Related Experiment Video
Updated: Aug 15, 2026
High Throughput Screening of Fungal Endoglucanase Activity in Escherichia coli
Published on: August 13, 2011
Abstract:
Ecteinascidin-743 (ET-743) is a marine-derived antineoplastic agent undergoing clinical trials to evaluate its use in the treatment of a variety of solid tumors. After the completion of the phase I studies, the agent subsequently was investigated in phase II trials for efficacy in a variety of tumor types. Ongoing phase I evaluation continues with other antineoplastic agents. Side effects of ET-743 include myelosuppression, hepatotoxicity, and nausea and vomiting. Liver function test monitoring is crucial and useful in predicting other serious toxicities. Nursing care issues and patient education are discussed in this article.
Insights
Ecteinascidin-743 (ET-743), a marine-derived cancer drug, is being tested in clinical trials for solid tumors. Monitoring liver function is key to managing side effects like myelosuppression and hepatotoxicity.
Area of Science:
- Marine biotechnology
- Pharmacology
- Oncology
Background:
- Ecteinascidin-743 (ET-743) is a novel marine-derived antineoplastic agent.
- Clinical trials are evaluating its efficacy in treating various solid tumors.
Purpose of the Study:
- To review the clinical trial progress of ET-743.
- To highlight key toxicities and nursing considerations for ET-743 administration.
Main Methods:
- Phase I and II clinical trial data review.
- Analysis of adverse events and patient management strategies.
Main Results:
- ET-743 has shown promise in phase II trials for solid tumors.
- Common side effects include myelosuppression, hepatotoxicity, nausea, and vomiting.
- Liver function tests are critical for predicting and managing toxicities.
Conclusions:
- ET-743 is a significant marine-derived agent for solid tumor treatment.
- Close monitoring of liver function and patient education are essential for safe and effective use.
- Further research and ongoing trials continue to explore ET-743's potential.
